Substance P serum levels are increased in major depression: preliminary results.
about
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic responseQuality of life and pain in premenopausal women with major depressive disorder: the POWER Study.Unexplained Painful Physical Symptoms in Patients with Major Depressive Disorder: Prevalence, Pathophysiology and ManagementBiological and Pharmacological Aspects of the NK1-ReceptorEmerging targets for antidepressant therapiesNovel targets for antidepressant therapiesInvolvement of midbrain tectum neurokinin-mediated mechanisms in fear and anxietyEffects of fluoxetine on mast cell morphology and protease-1 expression in gastric antrum in a rat model of depressionIncreased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia.The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disordersA new mouse model for mania shares genetic correlates with human bipolar disorder.Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists.Stuck in a rut: rethinking depression and its treatment.Advances in the treatment of depressionMeasurement of plasma-derived substance P: biological, methodological, and statistical considerations.Clinical characteristics of pruritus in patients with scalp psoriasis and their relation with intraepidermal nerve fiber density.Future prospects in depression researchAdvances in the Management of Treatment-Resistant DepressionSubstance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation.NK1 receptor antagonists under investigation for the treatment of affective disorders.Emerging treatments for depression.Molecular genetic findings in suicidal behavior: what is beyond the serotonergic system?Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in ratsCommon mechanisms of pain and depression: are antidepressants also analgesics?Alterations in splenic function and gene expression in mice with depressive-like behavior induced by exposure to corticosterone.An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets.The role of substance p in ischaemic brain injury.The association between substance P and white matter integrity in medication-naive patients with major depressive disorder.Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat.Novel method for determination of substance P levels in unextracted human plasma by using acidification.Substance P alterations in skin and brain of chronically stressed atopic-like mice.Depressive Disorders: Major Depressive Disorder and Persistent Depressive DisorderMedial Habenula-Interpeduncular Nucleus Circuit Contributes to Anhedonia-Like Behavior in a Rat Model of Depression
P2860
Q24567550-0855DBF8-39F2-4140-915B-6BB7DA7251D6Q25256599-D5182701-2A95-4E00-9F45-62F0043A0E7BQ26751458-89000962-3480-474C-9AB0-7CEB5D7C08DAQ26784074-D34E8A17-0580-4AC6-B23A-33B09CCC6B4DQ28247614-2B81BC2D-DB31-43A1-9A31-23D41C936275Q28648254-5A747B49-DA6E-4390-91E7-D36F38D7E4AAQ30445747-03063B23-261B-43FA-8B73-B4F828DE87E1Q33389951-543F9565-C6B0-45A8-9F43-F4A117F2063EQ33990603-7A25C12A-7B08-434A-913E-1EEF9341653EQ34259043-15DA0237-A84E-4DB1-A5E9-8E9DAF8CED18Q34295707-10DEB735-8688-4D72-A0A2-4B46D808D124Q34376340-BACDBD82-3F39-44EF-BAF7-AE1D6454FFCEQ34459160-74B61D9B-5881-4B9B-AF45-E7EA2CED1D25Q34496251-9FCFD6A7-55A7-4016-AFC0-73D9F29A789CQ34565970-16141DF8-1117-45D9-A789-104AA2B1974DQ34615344-91A679C0-4297-40E0-A51F-1D5BE7E2066CQ35236701-E10690E3-DBF2-4B0A-9644-38486911896AQ35580600-32AEBF6D-572D-422D-8137-3EB4FD578789Q36205025-B2E74AB0-C311-4C42-8383-5AC5EC464DA4Q36458364-6780260B-E0AE-4C3D-BC32-45F7D4E63DC2Q36655168-B17A5F5B-EA10-4B9A-8348-F12A91E7710BQ36687973-D4B4F440-5CF0-492C-B956-ED82A99B1BC2Q37357071-CAB7CD8E-B440-41EA-B2C5-4A65DE8AA8F1Q37676446-A3B30562-BEDB-4DF5-B82C-73D45FEE187BQ37711960-99C87B7C-DC44-46A1-9F8D-D985411965E2Q38167857-FECF61F8-E444-4755-830E-88CBB3506214Q38222871-D82AA2C6-1FF0-4941-ADE0-F7499237E9BBQ41550669-3E5B7DAA-ACCB-4A7F-9FC4-504AA5F37828Q41950122-4B62D28D-BF69-4E87-822F-835B681E0545Q43146586-1940AAA2-292C-4DAF-8293-38A187B2EEAFQ48710318-174F0B14-32DE-4225-AC8F-7DBF3035FC5AQ57703141-F34F2E9E-6E03-44E8-ABD8-8E0B91B9355AQ57816581-E9ED655C-6124-42FD-A392-771E1624AA50
P2860
Substance P serum levels are increased in major depression: preliminary results.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Substance P serum levels are increased in major depression: preliminary results.
@en
type
label
Substance P serum levels are increased in major depression: preliminary results.
@en
prefLabel
Substance P serum levels are increased in major depression: preliminary results.
@en
P2093
P1476
Substance P serum levels are increased in major depression: preliminary results.
@en
P2093
Brigitta Bondy
Christo Minov
Cornelius Schüle
Hans J ürgen Möller
Markus J Schwarz
Peter Zwanzger
Rainer Rupprecht
Thomas C Baghai
P304
P356
10.1016/S0006-3223(02)01544-5
P407
P577
2003-03-01T00:00:00Z